Here are five observations:
1. The product is an alternative to autograft for ankle and/or hind foot fusion indications.
2. Wright Medical acquired the Augment product under its $380 million deal with BioMimetic Therapeutics in November 2012.
3. The company started selling Augment products in international markets and then applied for an U.S. FDA approval.
4. The product is made up of recombinant human platelet-derived growth factor and beta-tricalcium phosphate.
5. Wright Medical is an orthopedic device company, focusing on the design, manufacture and marketing of reconstructive joint devices and bio-orthopedic materials.
More articles on devices:
Frankfurt University Hospital purchases ROSA robotic surgery system
Alexander Bone & Spine in Miami offering SCS implants
TranS1 names new vice president of sales
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
